Morgan Stanley Rapt Therapeutics, Inc. Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,178,895 shares of RAPT stock, worth $2.63 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,178,895
Previous 1,905,334
38.13%
Holding current value
$2.63 Million
Previous $17.1 Million
78.99%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding RAPT
# of Institutions
126Shares Held
29.2MCall Options Held
905KPut Options Held
592K-
Vanguard Group Inc Valley Forge, PA3.11MShares$6.93 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$5.98 Million11.48% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$5.44 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$3.85 Million0.61% of portfolio
-
Ponoi Management, LLC San Francisco, CA1.6MShares$3.57 Million52.54% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $66.1M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...